Elutia Inc.
US ˙ NasdaqCM ˙ US05479K1060

Introduction

This page provides a comprehensive analysis of the known insider trading history of Kevin Rakin. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Kevin Rakin has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ELUT / Elutia Inc. Director, 10% Owner 9,520,232
US:QSI / Quantum-Si incorporated Director 1,200,000
US:ORMP / Oramed Pharmaceuticals Inc. Director 46,661
US:HSGX / Histogenics Corporation Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Kevin Rakin. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ELUT / Elutia Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ELUT / Elutia Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2022-12-05 AZYO HighCape Capital, L.P. 735,000 4.7500 735,000 4.7500 3,491,250 60 4.9600 154,350 4.42
2021-12-08 AZYO HighCape Capital, L.P. 353,773 4.2400 353,773 4.2400 1,499,998
2021-12-08 AZYO HighCape Capital, L.P. 58,962 4.2400 58,962 4.2400 249,999
2020-10-13 AZYO HighCape Capital, L.P. 441,176 17.0000 441,176 17.0000 7,499,992

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ELUT / Elutia Inc. Insider Trades
Insider Sales ELUT / Elutia Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ELUT / Elutia Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ELUT / Elutia Inc. Insider Trades
Insider Purchases OCGN / Ocugen, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ELUT / Elutia Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2018-10-10 HSGX RAKIN KEVIN 230,768 230,768 8
2014-12-08 HSGX RAKIN KEVIN 6,742 11.0000 6,742 11.0000 74,162
2014-12-08 HSGX RAKIN KEVIN 4,495 11.0000 4,495 11.0000 49,445

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

OCGN / Ocugen, Inc. Insider Trades
Insider Sales OCGN / Ocugen, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ELUT / Elutia Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2014-12-08 HSGX RAKIN KEVIN 17 11.0000 17 11.0000 187 731

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

OCGN / Ocugen, Inc. Insider Trades
Insider Purchases ORMP / Oramed Pharmaceuticals Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ELUT / Elutia Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ORMP / Oramed Pharmaceuticals Inc. Insider Trades
Insider Sales ORMP / Oramed Pharmaceuticals Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ELUT / Elutia Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2022-03-21 ORMP RAKIN KEVIN 10,000 9.4096 10,000 9.4096 94,096 311 1.9300 -74,796 -79.49
2021-09-16 ORMP RAKIN KEVIN 21,100 20.9872 21,100 20.9872 442,830

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ORMP / Oramed Pharmaceuticals Inc. Insider Trades
Insider Purchases QSIAW / Quantum-Si incorporated - Equity Warrant - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ELUT / Elutia Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

QSIAW / Quantum-Si incorporated - Equity Warrant Insider Trades
Insider Sales QSIAW / Quantum-Si incorporated - Equity Warrant - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ELUT / Elutia Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2022-12-15 QSI RAKIN KEVIN 89,000 2.1487 89,000 2.1487 191,234 316 1.1450 -89,329 -46.71

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

QSIAW / Quantum-Si incorporated - Equity Warrant Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Kevin Rakin as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-03-13 2025-02-03 4 ELUT ELUTIA INC.
Class A Common Stock
P - Purchase 420,000 9,520,232 4.62 2.50 1,050,000 23,800,580
2024-08-01 2024-07-30 4 ELUT ELUTIA INC.
Class A Common Stock
X - Other 2,101,577 9,100,232 30.03 1.43 3,000,001 12,990,581
2024-01-08 2023-12-28 4 ELUT ELUTIA INC.
Class A Common Stock
J - Other -1,436,077 6,998,655 -17.03
2023-10-05 2021-09-21 4 ELUT ELUTIA INC.
Class A Common Stock
P - Purchase 2,837,128 8,434,732 50.68
2022-12-22 2022-12-20 4 QSI Quantum-Si Inc
Class A Common Stock
J - Other -601,000 1,200,000 -33.37
2022-12-16 2022-12-15 4 QSI Quantum-Si Inc
Class A Common Stock
S - Sale -89,000 1,801,000 -4.71 2.15 -191,234 3,869,809
2022-12-07 2022-12-05 4 AZYO AZIYO BIOLOGICS, INC.
Class A Common Stock
P - Purchase 735,000 5,597,604 15.12 4.75 3,491,250 26,588,619
2022-05-13 2022-05-11 4 QSI Quantum-Si Inc
Stock Option (right to buy)
A - Award 59,880 59,880
2022-03-22 2022-03-21 4 ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
S - Sale -10,000 46,661 -17.65 9.41 -94,096 439,061
2022-02-22 2022-02-17 4 ORMP ORAMED PHARMACEUTICALS INC.
Stock Option (right to buy)
M - Exercise -6,667 0 -100.00
2022-02-22 2022-02-17 4 ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
F - Taxes -3,010 56,661 -5.04 10.63 -31,996 602,306
2022-02-22 2022-02-17 4 ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
M - Exercise 6,667 59,671 12.58 4.80 32,002 286,421
2022-02-15 2022-02-11 4/A ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
G - Gift -5,000 53,004 -8.62
2022-02-14 2022-02-11 4 ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
G - Gift -5,000 47,004 -9.61
2022-02-10 2021-11-03 5 QSI Quantum-Si Inc
Class A Common Stock
G - Gift -11,000 1,890,000 -0.58
2022-01-05 2022-01-03 4 ORMP ORAMED PHARMACEUTICALS INC.
Stock Option (right to buy)
A - Award 10,000 10,000
2022-01-05 2022-01-03 4 ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
A - Award 6,000 58,004 11.54
2021-12-17 2021-12-16 4 ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
G - Gift -5,000 52,004 -8.77
2021-12-10 2021-12-08 4 AZYO AZIYO BIOLOGICS, INC.
Class A Common Stock
P - Purchase 58,962 90,807 185.15 4.24 249,999 385,022
2021-12-10 2021-12-08 4 AZYO AZIYO BIOLOGICS, INC.
Class A Common Stock
P - Purchase 353,773 4,862,604 7.85 4.24 1,499,998 20,617,441
2021-09-20 2021-09-16 4 ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
S - Sale -21,100 57,004 -27.02 20.99 -442,830 1,196,354
2021-09-02 2021-08-31 4 ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
A - Award 10,000 78,104 14.68
2021-08-11 2021-08-09 4 ORMP ORAMED PHARMACEUTICALS INC.
Stock Option (right to buy)
M - Exercise -56,773 0 -100.00
2021-08-11 2021-08-09 4 ORMP ORAMED PHARMACEUTICALS INC.
Stock Option (right to buy)
M - Exercise -10,000 0 -100.00
2021-08-11 2021-08-09 4 ORMP ORAMED PHARMACEUTICALS INC.
Stock Option (right to buy)
M - Exercise -6,666 0 -100.00
2021-08-11 2021-08-09 4 ORMP ORAMED PHARMACEUTICALS INC.
Stock Option (right to buy)
M - Exercise -5,697 0 -100.00
2021-08-11 2021-08-09 4 ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
F - Taxes -20,916 68,104 -23.50 21.09 -441,118 1,436,313
2021-08-11 2021-08-09 4 ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
M - Exercise 56,773 89,020 176.06 7.77 441,126 691,685
2021-08-11 2021-08-09 4 ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
F - Taxes -1,977 32,247 -5.78 21.09 -41,695 680,089
2021-08-11 2021-08-09 4 ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
M - Exercise 10,000 34,224 41.28 4.17 41,700 142,714
2021-08-11 2021-08-09 4 ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
F - Taxes -1,517 24,224 -5.89 21.09 -31,994 510,884
2021-08-11 2021-08-09 4 ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
M - Exercise 6,666 25,741 34.95 4.80 31,997 123,557
2021-08-11 2021-08-09 4 ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
F - Taxes -1,683 19,075 -8.11 21.09 -35,494 402,292
2021-08-11 2021-08-09 4 ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
M - Exercise 5,697 20,758 37.83 6.23 35,492 129,322
2021-06-15 2021-06-11 4 QSI Quantum-Si Inc
Class A Common Stock
A - Award 20,512 20,512
2021-06-15 2021-06-10 4 QSI Quantum-Si Inc
Class A Common Stock
A - Award 1,901,000 1,901,000 10.00 19,010,000 19,010,000
2021-06-09 2021-06-07 4 AZYO AZIYO BIOLOGICS, INC.
Stock Option (Right to Buy)
A - Award 14,082 14,082
2021-06-09 2021-06-07 4 AZYO AZIYO BIOLOGICS, INC.
Stock Option (Right to Buy)
A - Award 14,082 14,082
2021-02-17 2021-02-17 4 ORMP ORAMED PHARMACEUTICALS INC.
Stock Option (right to buy)
A - Award 15,000 15,000
2020-10-13 2020-10-13 4 AZYO AZIYO BIOLOGICS, INC.
Warrant
X - Other -7,655 0 -100.00
2020-10-13 2020-10-13 4 AZYO AZIYO BIOLOGICS, INC.
Series A Convertible Preferred Stock
C - Conversion -31,133,977 0 -100.00
2020-10-13 2020-10-13 4 AZYO AZIYO BIOLOGICS, INC.
Class A Common Stock
P - Purchase 441,176 4,508,831 10.85 17.00 7,499,992 76,650,127
2020-10-13 2020-10-13 4 AZYO AZIYO BIOLOGICS, INC.
Class A Common Stock
F - Taxes -2,451 4,067,655 -0.06 5.44 -13,339 22,137,806
2020-10-13 2020-10-13 4 AZYO AZIYO BIOLOGICS, INC.
Class A Common Stock
X - Other 7,655 4,070,106 0.19 5.44 41,662 22,151,145
2020-10-13 2020-10-13 4 AZYO AZIYO BIOLOGICS, INC.
Class A Common Stock
C - Conversion 4,062,451 4,062,451
2020-10-07 3 AZYO AZIYO BIOLOGICS, INC.
Class A Common Stock
31,845
2020-01-14 2020-01-08 4 ORMP ORAMED PHARMACEUTICALS INC.
Stock Option (right to buy)
A - Award 20,000 20,000
2019-09-16 2019-09-12 4 ORMP ORAMED PHARMACEUTICALS INC.
Stock Option (right to buy)
A - Award 10,000 10,000
2019-09-16 2019-04-10 4 ORMP ORAMED PHARMACEUTICALS INC.
Stock Option (right to buy)
D - Sale to Issuer -10,000 0 -100.00
2019-04-12 2019-04-10 4 ORMP ORAMED PHARMACEUTICALS INC.
Stock Option (right to buy)
A - Award 10,000 10,000
2019-02-11 2019-02-08 4 HSGX HISTOGENICS CORP
Common Stock Warrant (Right to Buy)
M - Exercise -111,111 0 -100.00
2019-02-11 2019-02-08 4 HSGX HISTOGENICS CORP
Common Stock Warrant (Right to Buy)
M - Exercise -33,333 0 -100.00
2019-02-11 2019-02-08 4 HSGX HISTOGENICS CORP
Common Stock Warrant (Right to Buy)
M - Exercise -33,333 0 -100.00
2019-02-11 2019-02-08 4 HSGX HISTOGENICS CORP
Common Stock Warrant (Right to Buy)
M - Exercise -173,076 0 -100.00
2019-02-11 2019-02-08 4 HSGX HISTOGENICS CORP
Common Stock
M - Exercise 111,111 257,846 75.72
2019-02-11 2019-02-08 4 HSGX HISTOGENICS CORP
Common Stock
M - Exercise 33,333 66,666 100.00
2019-02-11 2019-02-08 4 HSGX HISTOGENICS CORP
Common Stock
M - Exercise 33,333 66,666 100.00
2019-02-11 2019-02-08 4 HSGX HISTOGENICS CORP
Common Stock
M - Exercise 173,076 418,639 70.48
2018-10-11 2018-10-10 4 HSGX HISTOGENICS CORP
Common Stock Warrant (Right to Buy)
P - Purchase 173,076 173,076
2018-10-11 2018-10-10 4 HSGX HISTOGENICS CORP
Common Stock
P - Purchase 230,768 245,563 1,559.77
2018-06-19 2018-06-15 4 HSGX HISTOGENICS CORP
Stock Option (Right to Buy)
A - Award 25,000 25,000
2017-07-05 2017-06-30 4 ORMP ORAMED PHARMACEUTICALS INC.
Stock Option (right to buy)
A - Award 56,773 56,773
2017-06-14 2017-06-13 4 HSGX HISTOGENICS CORP
Stock Option (Right to Buy)
A - Award 25,000 25,000
2017-02-16 2017-02-09 4 ORMP ORAMED PHARMACEUTICALS INC.
Stock Option (right to buy)
A - Award 5,697 5,697
2016-12-19 2016-12-16 4 HSGX HISTOGENICS CORP
Stock Option (Right to Buy)
A - Award 10,000 10,000
2016-12-07 2016-12-06 4 ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
A - Award 3,300 15,061 28.06 6.59 21,763 99,324
2016-12-07 2016-12-05 4 ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
A - Award 2,300 11,761 24.31 6.38 14,665 74,989
2016-12-05 2016-12-02 4 ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
A - Award 7,261 9,461 330.05 6.21 45,057 58,709
2016-12-05 2016-12-01 4 ORMP ORAMED PHARMACEUTICALS INC.
Common Stock
A - Award 2,200 2,200 6.08 13,371 13,371
2016-12-02 2016-11-30 4 HSGX HISTOGENICS CORP
Series A Convertible Preferred Stock
C - Conversion -200 0 -100.00
2016-12-02 2016-11-30 4 HSGX HISTOGENICS CORP
Series A Convertible Preferred Stock
C - Conversion -60 0 -100.00
2016-12-02 2016-11-30 4 HSGX HISTOGENICS CORP
Series A Convertible Preferred Stock
C - Conversion -60 0 -100.00
2016-12-02 2016-11-30 4 HSGX HISTOGENICS CORP
Common Stock
C - Conversion 88,998 228,196 63.94
2016-12-02 2016-11-30 4 HSGX HISTOGENICS CORP
Common Stock
C - Conversion 26,699 139,198 23.73
2016-12-02 2016-11-30 4 HSGX HISTOGENICS CORP
Common Stock
C - Conversion 26,699 139,198 23.73
2016-10-03 2016-09-29 4 HSGX HISTOGENICS CORP
Common Stock Warrant (Right to Buy)
A - Award -111,111 177,777 -38.46
2016-10-03 2016-09-29 4 HSGX HISTOGENICS CORP
Common Stock Warrant (Right to Buy)
A - Award -33,333 66,666 -33.33
2016-10-03 2016-09-29 4 HSGX HISTOGENICS CORP
Common Stock Warrant (Right to Buy)
A - Award -33,333 66,666 -33.33
2016-10-03 2016-09-29 4 HSGX HISTOGENICS CORP
Series A Convertible Preferred Stock
A - Award -200 320 -38.46 1,000.00 -200,246 320,391
2016-10-03 2016-09-29 4 HSGX HISTOGENICS CORP
Series A Convertible Preferred Stock
A - Award -60 120 -33.33 1,000.00 -60,073 120,146
2016-10-03 2016-09-29 4 HSGX HISTOGENICS CORP
Series A Convertible Preferred Stock
A - Award -60 120 -33.33 1,000.00 -60,073 120,146
2016-10-03 2016-09-29 4 HSGX HISTOGENICS CORP
Common Stock
A - Award 22,113 85,800 34.72 2.25 49,754 193,050
2016-10-03 2016-09-29 4 HSGX HISTOGENICS CORP
Common Stock
A - Award 6,634 63,687 11.63 2.25 14,926 143,296
2016-10-03 2016-09-29 4 HSGX HISTOGENICS CORP
Common Stock
A - Award 6,634 63,687 11.63 2.25 14,926 143,296
2015-06-26 2015-06-24 4 HSGX HISTOGENICS CORP
Stock Option (Right to Buy)
A - Award 20,000 20,000
2014-12-08 2014-12-08 4 HSGX HISTOGENICS CORP
Series A-1 Preferred Stock
C - Conversion -3,914 0 -100.00
2014-12-08 2014-12-08 4 HSGX HISTOGENICS CORP
Series A Preferred Stock
C - Conversion -6,444 0 -100.00
2014-12-08 2014-12-08 4 HSGX HISTOGENICS CORP
Common Stock Warrant (Right to Buy)
X - Other -242 0 -100.00
2014-12-08 2014-12-08 4 HSGX HISTOGENICS CORP
Series A-1 Preferred Stock
C - Conversion -5,871 0 -100.00
2014-12-08 2014-12-08 4 HSGX HISTOGENICS CORP
Series A Preferred Stock
C - Conversion -9,667 0 -100.00
2014-12-08 2014-12-08 4 HSGX HISTOGENICS CORP
Common Stock
J - Other -58 50,420 -0.11
2014-12-08 2014-12-08 4 HSGX HISTOGENICS CORP
Common Stock
P - Purchase 4,495 50,478 9.78 11.00 49,445 555,258
2014-12-08 2014-12-08 4 HSGX HISTOGENICS CORP
Common Stock
C - Conversion 3,914 45,983 9.30
2014-12-08 2014-12-08 4 HSGX HISTOGENICS CORP
Common Stock
C - Conversion 6,444 42,069 18.09
2014-12-08 2014-12-08 4 HSGX HISTOGENICS CORP
Common Stock
J - Other -89 35,625 -0.25
2014-12-08 2014-12-08 4 HSGX HISTOGENICS CORP
Common Stock
P - Purchase 6,742 35,714 23.27 11.00 74,162 392,854
2014-12-08 2014-12-08 4 HSGX HISTOGENICS CORP
Common Stock
S - Sale -17 28,972 -0.06 11.00 -187 318,692
2014-12-08 2014-12-08 4 HSGX HISTOGENICS CORP
Common Stock
X - Other 242 28,989 0.84 0.76 184 22,032
2014-12-08 2014-12-08 4 HSGX HISTOGENICS CORP
Common Stock
C - Conversion 5,871 28,747 25.66
2014-12-08 2014-12-08 4 HSGX HISTOGENICS CORP
Common Stock
C - Conversion 9,667 22,985 72.59
2014-12-02 3 HSGX HISTOGENICS CORP
Common Stock
26,418
2014-12-02 3 HSGX HISTOGENICS CORP
Common Stock
26,418
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)